CN1085439A - A kind of anticancer herbal drug - Google Patents
A kind of anticancer herbal drug Download PDFInfo
- Publication number
- CN1085439A CN1085439A CN 93104960 CN93104960A CN1085439A CN 1085439 A CN1085439 A CN 1085439A CN 93104960 CN93104960 CN 93104960 CN 93104960 A CN93104960 A CN 93104960A CN 1085439 A CN1085439 A CN 1085439A
- Authority
- CN
- China
- Prior art keywords
- medicine
- herba phyllanthi
- phyllanthi urinariae
- anticancer
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of anticancer antiinflammatory Chinese herbal medicine and method for making thereof.The primary raw material of said anticancer herbal drug is the liliaceous plant Herba Phyllanthi Urinariae.The Herba Phyllanthi Urinariae can make patent medicine by separate constituent, also can cooperate pharmacy with Chinese medicines such as Radix Ginseng, Fructus Schisandrae Chinensis, Radix Salviae Miltiorrhizae, Scolopendras; Can also extract active constituents of medicine and make raw material, prepare acceptable dosage form in the various medical treatment.Through the animal pharmacology experiment, Herba Phyllanthi Urinariae's cancer suppressing ratio is in 30-60% scope, and no overt toxicity reaction is the new drug resource of treatment cancer and inflammation.
Description
The present invention relates to Chinese herbal medicine and method for making thereof that anticancer antiinflammatory is used.
Cancer is the formidable enemy of human health.The research cancer therapy drug effects a radical cure various cancers or suppresses the generation and the growth of tumor, is that people make great efforts the important topic that solves always.Particularly seeking the antitumor composition of high-efficiency low-toxicity from plant, make it become PTS, or cooperate with other Chinese herbal medicine, make the Chinese patent medicine of anticancer usefulness, is human health service to the exploitation medicine resource, is significant.
General anticancer Western medicine has cycli phosphate amine, and curative effect is better, but side effect also relatively significantly, takes this medicine and causes the interior leukocyte of blood obviously to descend alopecia.For reducing side effect, exploitation Chinese herbal treatment cancer is up-and-coming.FUFANG TIANXIAN JIAONANG is exactly the little Chinese medicine medicine for preventing of a kind of side effect.Its main component has: Radix Trichosanthis, Radix Clematidis, the Radix Astragali, Moschus, Calculus Bovis, Olibanum, Myrrha, Polyporus, Herba Hedyotidis Diffusae, Borneolum Syntheticum, the Rhizoma Atractylodis Macrocephalae, Fructus Ligustri Lucidi, Radix Glycyrrhizae etc., its function is: " heat-clearing and toxic substances removing, removing obstruction for relieving pain, benefiting qi and nourishing blood.The esophageal carcinoma, gastric cancer are had certain inhibitory action, and combined with chemotherapy, radiotherapy can improve its curative effect " (drawing) from this medicine explanation.
But the cancer suppressing ratio of FUFANG TIANXIAN JIAONANG is desirable not enough, and about in the of 30%, thereby curative effect is obvious inadequately.
The object of the present invention is to provide the PTS of the high curative effect of a kind of low toxicity.
Anticancer herbal drug of the present invention is liliaceous plant Herba Phyllanthi Urinariae (Ornithogalun Caudatum Ait), the popular name Herba Phyllanthi Urinariae.
The Herba Phyllanthi Urinariae originates in Africa south, has potted plantly in northern China, still belongs to ornamental plant.Now, the introducing and planting in some areas of Changbaishan area.Herba Phyllanthi Urinariae's herb has the heat reliving and toxin-eliminating effect, in useful its inflammation such as treatment parotitis, hepatitis among the people.Herba Phyllanthi Urinariae's avirulence, its main component alkaloid can suppress the synthetic of anaerobic ribonucleic acid, are main contents of the present invention as cancer therapy drug.
Treat cancer with the Herba Phyllanthi Urinariae, can use herb, promptly can using fresh herb, also can dry, dry the back and use.
The Herba Phyllanthi Urinariae is made anticancer patent medicine, also can with other Chinese herbal medicine compatibility, make powder, pill, tablet etc. with conventional way.Prescription when making powder, pill, tablet includes following medicine: Herba Phyllanthi Urinariae, Radix Ginseng, Fructus Schisandrae Chinensis, Radix Salviae Miltiorrhizae, Scolopendra.Can also comprise Scorpio, the Radix Astragali etc.Proportioning by weight is: the Herba Phyllanthi Urinariae 35～60%, Radix Ginseng 10～30%, Fructus Schisandrae Chinensis 8～25%, Radix Salviae Miltiorrhizae 10～30%, Scolopendra 1～5%.Consumption such as one pair of water decoction can be Herba Phyllanthi Urinariae 50g, Radix Ginseng 25g, Fructus Schisandrae Chinensis 15g, Radix Salviae Miltiorrhizae 25g, Scolopendra 3g.
The Herba Phyllanthi Urinariae is made anticancer patent medicine, can also extract its active drug active component, main component is an alkaloid.Method is routinely made powder, tablet, capsule, oral liquid or injection again.Extract alkaloidal method and also be conventional method, be about to former grass and dry pulverizing,, obtain the active constituents of medicine alkaloid through precipitation, recovery solvent with alcohol or other solvent soaking.
Aforesaid at the cancer therapy drug of the various dosage forms of acceptable pharmaceutically, its primary raw material is the Herba Phyllanthi Urinariae.Become the application of Herba Phyllanthi Urinariae in preparation treatment cancer drug in other words.
Herba Phyllanthi Urinariae of the present invention is as medicine, and the animal pharmacology experiment through crude drug powder proves that cancer suppressing ratio is in 30%～60% scope.Cancer suppressing ratio to various tumor strains is respectively: sarcoma 180 is 37～62%, and the cervix uteri tumor is 36～52%, and ehrlich carcinoma is 50～60%, and entity hepatocarcinoma is 31～57%.Above-mentioned cancer suppressing ratio is undertaken by 200～800mg/kg dosage, curative effect with 800mg/kg serves as remarkable, its curative effect is close with known anticancer Western medicine cycli phosphate amine 20mg/kg, and is better than the cancer suppressing ratio of the basic identical dosage of known Chinese medicine medicine for preventing FUFANG TIANXIAN JIAONANG.
Herba Phyllanthi Urinariae's The acute toxicity tests is not all found the overt toxicity reaction.Irritate the animal of stomach and give the former careless 10g/kg of Herba Phyllanthi Urinariae and two kinds of dosage of 20g/kg, none death; To immune organ weight influence experiment, immune function of mice there is not tangible influence.
As the easy artificial culture of the Herba Phyllanthi Urinariae of cancer therapy drug primary raw material of the present invention, can be made into the low toxicity of various dosage forms and anticarcinogen with higher curative effect, have the eliminating inflammation and expelling toxin function simultaneously again.Thereby the Herba Phyllanthi Urinariae is very promising drug resource.
Claims (3)
1, a kind of medicine of anticancer usefulness is the liliaceous plant Herba Phyllanthi Urinariae.
2,, it is characterized in that also including Radix Ginseng, Fructus Schisandrae Chinensis, Radix Salviae Miltiorrhizae, Scolopendra according to the medicine of the described anticancer usefulness of claim 1; Proportioning by weight is Herba Phyllanthi Urinariae 35-60%, Radix Ginseng 10-30%, Fructus Schisandrae Chinensis 8-25%, Radix Salviae Miltiorrhizae 10-30%, Scolopendra 1-5%.
3, a kind of manufacture method of cancer therapy drug is to make medical treatment with conventional method to go up the acceptable dosage form, and the primary raw material that the invention is characterized in pharmacy is Herba Phyllanthi Urinariae or the active constituents of medicine that extracts from the Herba Phyllanthi Urinariae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93104960 CN1085439A (en) | 1993-05-19 | 1993-05-19 | A kind of anticancer herbal drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93104960 CN1085439A (en) | 1993-05-19 | 1993-05-19 | A kind of anticancer herbal drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1085439A true CN1085439A (en) | 1994-04-20 |
Family
ID=4985482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 93104960 Pending CN1085439A (en) | 1993-05-19 | 1993-05-19 | A kind of anticancer herbal drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1085439A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1956725B (en) * | 2004-03-12 | 2010-05-26 | 根路铭国昭 | Antineoplastic agent |
| CN102652790A (en) * | 2011-04-02 | 2012-09-05 | 吉林修正药业新药开发有限公司 | Traditional Chinese medicine having effects of promoting blood circulation, removing stasis, dispersing swelling and relieving pain and preparation method of traditional Chinese medicine |
| CN104000998A (en) * | 2013-02-26 | 2014-08-27 | 陈清群 | Ornithogalum caudatum herbal tea |
| CN112675249A (en) * | 2021-01-20 | 2021-04-20 | 邱淑琴 | Compound preparation of star-of-Bethlehem and preparation technology thereof |
| CN113082174A (en) * | 2021-04-08 | 2021-07-09 | 邱淑琴 | Preparation method of tiger eye perpetual green ointment |
| CN113101271A (en) * | 2021-04-08 | 2021-07-13 | 邱淑琴 | Tiger eye rohdea japonica granules and compound preparation technology thereof |
-
1993
- 1993-05-19 CN CN 93104960 patent/CN1085439A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1956725B (en) * | 2004-03-12 | 2010-05-26 | 根路铭国昭 | Antineoplastic agent |
| CN102652790A (en) * | 2011-04-02 | 2012-09-05 | 吉林修正药业新药开发有限公司 | Traditional Chinese medicine having effects of promoting blood circulation, removing stasis, dispersing swelling and relieving pain and preparation method of traditional Chinese medicine |
| CN104000998A (en) * | 2013-02-26 | 2014-08-27 | 陈清群 | Ornithogalum caudatum herbal tea |
| CN112675249A (en) * | 2021-01-20 | 2021-04-20 | 邱淑琴 | Compound preparation of star-of-Bethlehem and preparation technology thereof |
| CN113082174A (en) * | 2021-04-08 | 2021-07-09 | 邱淑琴 | Preparation method of tiger eye perpetual green ointment |
| CN113101271A (en) * | 2021-04-08 | 2021-07-13 | 邱淑琴 | Tiger eye rohdea japonica granules and compound preparation technology thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893722B (en) | A kind of Chinese medicine composition and its preparation method treating sunburn | |
| CN103520607B (en) | Traditional Chinese medicine preparation used for treating gastritis | |
| CN101342271B (en) | Traditional Chinese medicine for treating qi-blood deficiency caused by tumour chemotherapy and preparation method thereof | |
| CN103768398A (en) | Traditional Chinese medicine composition for treating advanced lung tumors | |
| CN101569739B (en) | Traditional Chinese medicine composition for treating cholecystitis and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN101564464B (en) | Chinese medicament for adjusting organism immunity of tumor patients | |
| CN101284107A (en) | Medicine for curing cancers and preparation method thereof | |
| CN1085439A (en) | A kind of anticancer herbal drug | |
| CN104825817B (en) | A kind of Chinese medicine preparation with antitumor action | |
| CN107823293A (en) | Treat Yao nationality medicine external pulvis of canker sore and preparation method thereof | |
| CN112494614A (en) | Chinese medicinal formula for preventing and treating cancer by using combination of pawpaw and various medicines | |
| CN1079252C (en) | Compound graceful jassamine preparation | |
| CN104083708A (en) | Traditional Chinese medicine ointment for treating scapulohumeral periarthritis | |
| CN110123896B (en) | Pharmaceutical composition for adjuvant treatment of tumor and preparation method thereof | |
| CN101085185A (en) | Beverage containing white peony root and gardenia | |
| CN105616961A (en) | Cancer chemoradiotherapy adjuvant-therapy traditional Chinese medicine and preparation method thereof | |
| CN106237156A (en) | A kind of Chinese medicine composition treating gastric cancer and preparation method thereof | |
| CN104825977A (en) | Traditional Chinese medicine composition for treating spleen deficiency food damage type postpartum food damage and preparation method of traditional Chinese medicine composition | |
| CN105169277A (en) | Fructus gardeniae oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof | |
| CN114869987A (en) | A Chinese medicinal composition for preventing and treating hepatocarcinoma | |
| CN103736008A (en) | Medicament composition for treating breast carcinoma concurrent uninjured side benign enclosed mass and preparation method thereof | |
| CN103704346A (en) | Instant milk tea powder for improving body function of lung cancer patient | |
| CN102579764B (en) | Traditional Chinese medicine for preventing and curing recurrent aphthae and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |